Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care stories included speculation regarding who would replace Tom Price, MD, as HHS secretary; a report on breast cancer mortality trends and racial disparities from 1989 to 2015; and the FDA announced new strategies to improve patient access to less expensive drugs.
Read more about the stories in this episode:
What We're Reading: Replacing Price; CHIP Deadline Passes; STDs in America
Drop in Breast Cancer Death Rate Saved More Than 322,000 Lives From 1989 to 2015
Kim Woofter on the Importance of Outside Partnerships for Community Oncology Practices
Latest FDA Efforts to Expand Access Involve Complex Generic Drugs, Investigational Treatments
Afrezza Gets Label Update; MannKind to Launch New Talks With Payers
Fast-Acting Insulin Aspart for Mealtime Gains FDA Approval
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More